Clozapine

Indications

• Treatment-resistant schizophrenia, defined as failure of two adequate trials of other antipsychotics, where clozapine is uniquely and substantially superior.
• Reduction of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder judged to be at chronic risk.
• Guidelines place it after two failed adequate antipsychotic trials, yet it is typically delayed by years, which costs response rates.
• Off-label uses include psychosis in Parkinson disease at low doses, tardive dyskinesia, and refractory aggression in schizophrenia.
• Also used off-label in treatment-resistant bipolar disorder, where evidence is weaker but clinically meaningful in refractory cases.

Mechanism of action

• Low-affinity, rapidly dissociating D2 antagonist with high D4 and very high 5-HT2A affinity, a profile no other agent reproduces.
• Weak striatal D2 occupancy explains why clozapine causes almost no extrapyramidal symptoms and can treat tardive dyskinesia.
• Potent muscarinic effects are mixed, with M1 antagonism causing dry mouth and constipation while M4 agonism drives paradoxical sialorrhea.
• Strong histamine H1 and alpha-1 blockade produce the sedation, weight gain, and orthostatic hypotension that dominate early treatment.
• The reason for its unique efficacy in resistant illness remains unexplained by receptor occupancy alone and is still an active question.

Pharmacokinetics

• Absorption is essentially complete and food independent, with bioavailability near 27 percent after substantial first-pass metabolism.
• Metabolized mainly by CYP1A2, with CYP3A4 and CYP2D6 secondary, to norclozapine, an active metabolite used in level interpretation.
• Mean half-life is about 12 hours with wide interindividual variation, supporting divided or predominantly evening dosing.
• Cigarette smoke induces CYP1A2 and lowers levels by 30-50 percent, so stopping smoking abruptly can push levels into toxicity.
• Women, nonsmokers, older adults, and patients with infection or inflammation all show higher levels at the same milligram dose.

Dosing

• Start 12.5 mg once or twice daily, then increase by 25-50 mg/day as tolerated to reach 300-450 mg/day in divided doses by the end of week 2.
• Subsequent increases should be no more than 100 mg once or twice weekly, with a labeled maximum of 900 mg/day.
• Most responders sit between 300 and 600 mg/day, and a trough level of at least 350 ng/mL should be documented before calling it a failure.
• If treatment is interrupted for 2 days or more, restart at 12.5 mg once or twice daily and retitrate, because hypotension risk resets.
• Reduce the dose by roughly half in significant renal or hepatic impairment, and titrate more slowly in older adults.
• Taper over at least 1-2 weeks when stopping electively, since abrupt withdrawal causes cholinergic rebound and rapid psychotic relapse.

Adverse effects

• Severe neutropenia occurs in about 1 percent and is the reason for absolute neutrophil count monitoring throughout treatment.
• Constipation is near universal and can progress to ileus, bowel obstruction, and death; it is a more common cause of mortality than agranulocytosis.
• Sedation, sialorrhea, tachycardia, orthostatic hypotension, and weight gain of 4-10 kg are expected rather than exceptional.
• Seizure risk is dose related, reaching about 5 percent above 600 mg/day, and often prompts adding valproate for prophylaxis.
• Myocarditis typically presents in weeks 2 to 4 with fever, tachycardia, chest pain, or dyspnea, and cardiomyopathy can appear later.
• Metabolic burden is the highest in the class alongside olanzapine, with high rates of new diabetes and severe hypertriglyceridemia.

Monitoring

• Obtain a baseline ANC and do not start if it is below 1500/uL, or below 1000/uL in benign ethnic neutropenia, also called Duffy-null neutrophil count.
• Monitor ANC weekly for 6 months, then every 2 weeks through month 12, then monthly, with more frequent testing after any interruption or fever.
• Interrupt for ANC 500-999/uL and discontinue permanently for ANC below 500/uL, obtaining hematology consultation in both cases.
• Watch for myocarditis in the first 8 weeks with troponin, C-reactive protein, and clinical review; discontinue if troponin exceeds twice the upper limit.
• Ask about bowel movements at every visit and start a bowel regimen prophylactically, plus routine metabolic labs and periodic clozapine levels.

Interactions

• Starting or stopping cigarettes changes CYP1A2 induction and can shift levels by 50 percent or more, a frequent cause of toxicity after admission.
• Fluvoxamine and ciprofloxacin are potent CYP1A2 inhibitors that can multiply clozapine levels severalfold and precipitate seizures or delirium.
• Avoid carbamazepine because of additive bone marrow suppression, and be cautious with other myelosuppressive agents.
• Benzodiazepines, especially given parenterally during titration, have been associated with respiratory arrest and profound hypotension.
• Anticholinergics and opioids compound constipation and are the usual co-factors in clozapine-associated ileus.

Special populations

• The Clozapine REMS was eliminated by the FDA in 2025, but the labeled ANC monitoring schedule remains and should still be followed.
• In pregnancy clozapine is not withheld from a stabilized patient; monitor the neonate for neutropenia, sedation, and floppy infant syndrome.
• Clozapine concentrates in breast milk and infant agranulocytosis has been reported, so breastfeeding is generally discouraged.
• Not approved in pediatric patients, though it is used in refractory childhood-onset schizophrenia with more sedation and seizures.
• Older adults need lower doses and slower titration given orthostasis, anticholinergic load, and ileus risk.

Clinical pearls

• Constipation kills more clozapine patients than agranulocytosis; prescribe a laxative on day one.
• Fever in weeks 2-4 means check troponin and CRP for myocarditis, not just an ANC.
• A level under 350 ng/mL means the trial was never adequate, whatever the milligram dose.